Legend Biotech Corporation (LEGN)

TheFly reported on February 4 that Barclays lowered its price target on LEGN to $80 from $90 and maintained an Overweight rating on the shares. Although the long-term forecast for the company's clinical...

On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 price target.

Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.

2025 was a year characterized by both challenges and opportunities for the biotechnology sector.

In a board shakeup last month, Legend Biotech Corp (NASDAQ:LEGN) appointed chairman and executive director of a major shareholder, GenScript, Robin Meng, as a Class III director to serve until the company...

Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S.

TheFly reported on January 22 that H.C. Wainwright lowered LEGN’s price target to $50 from $60 but kept a Buy rating, noting Q4 Carvykti sales of $555M missed the $582M consensus.

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best US stocks to buy under $50.